Product Details
| Product Name:
NNK |
CAS No.:
64091-91-4 |
| Purity:
99.92% |
Supply Ability:
10g |
| Release date:
2026/05/26 |
Product Introduction
Bioactivity
| Name | NNK |
| Description | NNK is a nitrosated derivative of nicotine that activates the ERK1/2 and PKCα signaling pathways, induces Bcl2 phosphorylation at Ser70, and activates c-Myc at Thr58 and Ser62, thereby promoting the proliferation and survival of human lung cancer cells, and is commonly used to establish lung cancer mouse models. |
| In vitro | METHODS: CL1.0 cells were seeded in 96-well plates and treated with 0, 3 or 10 nM NNK for 24 h, followed by MTT to measure cell viability. Cells treated with 0 or 10 nM NNK for 24 h were collected and analyzed by RT-PCR. The expression of α3, α4, α5 and α7 was detected. GAPDH was used as internal control. Cells were also preincubated with -bungarotoxin (Bun, 10 nM) for 2 h and then stimulated with NNK (+, 10 nM) without (?) for 24 h. Study contactin-1 protein levels and mRNA expression.
RESULTS NNK increased contactin-1 protein levels and up-regulated contactin-1 mRNA in a dose-dependent manner, indicating that NNK may directly stimulate gene transcription and cause CL1.0 cells to exhibit weaker toxic effects. [3] |
| In vivo | METHODS: Female A/J mice (7 weeks old) were treated with eight consecutive doses of NNK (3 μmol per week) by intragastric gavage (i.g.) or intraperitoneal injection, and the carcinogenesis of the mice was observed. RESULTS After 26 weeks, all mice developed lung adenomas. [1] METHODS: F344 rats were administered subcutaneously three times a week for 20 weeks with a total dose of 702 mg. The carcinogenesis of the mice was observed after 12 months. RESULTS 67% of the rats developed lung cancer. [2] |
| Storage | Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 20 mg/mL (96.51 mM), Solution.
DMSO : 247.5 mg/mL (1194.33 mM), Sonication is recommended.
|
| Keywords | Phosphorylation | NNK | Nicotine-nitrosated derivative | Lung cancer | LOX | Inhibitor | inhibit | Endogenous Metabolite | c-Myc | Cell proliferation | Bcl2 |
| Inhibitors Related | 2,5-Di-tert-butylhydroquinone | Caffeic Acid | 5-LOX inhibitor | 3-Aminobutanoic acid | Phenidone | 4-Aminosalicylic acid | Cuminaldehyde | Shogaol | PF-4191834 | Malotilate | 5-Aminosalicylic Acid | Tebufelone |
| Related Compound Libraries | Ferroptosis Compound Library | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | Tobacco Monomer Library | NO PAINS Compound Library | Metabolism Compound Library | Human Endogenous Metabolite Compound Library Plus | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Human Metabolite Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States